DBV Technologies S.A. (DBVT)
NASDAQ: DBVT · Real-Time Price · USD
3.190
+0.140 (4.59%)
At close: Dec 20, 2024, 4:00 PM
3.030
-0.160 (-5.02%)
After-hours: Dec 20, 2024, 4:06 PM EST
DBV Technologies Revenue
DBV Technologies had revenue of $1.07M in the quarter ending September 30, 2024, a decrease of -54.81%. This brings the company's revenue in the last twelve months to $12.52M, up 125.54% year-over-year. In the year 2023, DBV Technologies had annual revenue of $15.73M with 224.69% growth.
Revenue (ttm)
$12.52M
Revenue Growth
+125.54%
P/S Ratio
n/a
Revenue / Employee
$119,190
Employees
105
Market Cap
59.31M
Revenue Chart
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Dec 31, 2023 | 15.73M | 10.88M | 224.69% |
Dec 31, 2022 | 4.84M | -864.00K | -15.14% |
Dec 31, 2021 | 5.71M | -5.57M | -49.38% |
Dec 31, 2020 | 11.28M | -3.43M | -23.33% |
Dec 31, 2019 | 14.71M | 3.52M | 31.49% |
Dec 31, 2018 | Pro | Pro | Pro |
Dec 31, 2017 | Pro | Pro | Pro |
Dec 31, 2016 | Pro | Pro | Pro |
Dec 31, 2015 | Pro | Pro | Pro |
Dec 31, 2014 | Pro | Pro | Pro |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
CareCloud | 111.01M |
Repare Therapeutics | 66.52M |
Scilex Holding Company | 50.83M |
Apyx Medical | 48.54M |
Kronos Bio | 9.86M |
Dyadic International | 3.36M |
Pheton Holdings | 572.29K |
DBVT News
- 9 days ago - DBV Aligns With FDA On Accelerated Approval For Viaskin Peanut Patch In Younger Kids - Benzinga
- 10 days ago - DBV Confirms Alignment with U.S. FDA on Accelerated Approval Pathway for the Viaskin® Peanut Patch in Toddlers 1 – 3 Years-Old - GlobeNewsWire
- 5 weeks ago - DBV Technologies Announces Plan to Implement ADS Ratio Change - GlobeNewsWire
- 6 weeks ago - DBV Technologies Reports Third Quarter 2024 Financial Results - GlobeNewsWire
- 2 months ago - DBV Announces Positive Regulatory Updates for the Viaskin® Peanut Patch in the United States and Europe - GlobeNewsWire
- 2 months ago - DBV Technologies to Participate in Upcoming ACAAI 2024 Congress - GlobeNewsWire
- 3 months ago - DBV Technologies Completes Screening for the VITESSE Phase 3 Clinical Trial - GlobeNewsWire
- 3 months ago - DBV Technologies to Participate in the H.C. Wainwright 26th Annual Global Investment Conference - GlobeNewsWire